QQ客服 官方微博 反馈留言

	Phase I/II Study of AC0010, Mutant Selective EGFR Inhibitor, in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation
	Wu, Yi Long; Zhou, Qing; Liu, Xiaoqing; Zhang, Li; Zhou, Jianying; Wu, Lin; An, Tongtong; Cheng, Ying; Zheng, Xin; Hu, Bei
	2017
卷号	12期号:1页码:S437-S438
关键词	Phase I/II study NSCLC T790M AC0010
ISSN号	1556-0864
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6362002
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Wu, Yi Long,Zhou, Qing,Liu, Xiaoqing,et al. Phase I/II Study of AC0010, Mutant Selective EGFR Inhibitor, in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation[J],2017,12(1):S437-S438.
APA	Wu, Yi Long.,Zhou, Qing.,Liu, Xiaoqing.,Zhang, Li.,Zhou, Jianying.,...&Xu, Xiao.(2017).Phase I/II Study of AC0010, Mutant Selective EGFR Inhibitor, in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation.,12(1),S437-S438.
MLA	Wu, Yi Long,et al."Phase I/II Study of AC0010, Mutant Selective EGFR Inhibitor, in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation".12.1(2017):S437-S438.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。